Corpus ID: 42637469

Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.

@article{James1995SaquinavirF,
  title={Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.},
  author={J. James},
  journal={AIDS treatment news},
  year={1995},
  volume={no 237},
  pages={
          1-2
        }
}
  • J. James
  • Published 1995
  • Medicine
  • AIDS treatment news
  • Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the Food and Drug Administration (FDA) for use in combination with one or more unspecified nucleoside analogs. Rifampin should not be taken with saquinavir, and rifabutin should be only cautiously used in combination with saquinavir. Protease inhibitors have shown T-cell increases and viral load reductions similar to AZT when taken at the present low dosage. Research is… CONTINUE READING
    9 Citations
    HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors
    • 8
    • PDF
    Saquinavir‐NO Inhibits IL‐6 Production in Macrophages
    • 3
    Global and National trends of HIV/AIDS
    • PDF
    Risk-Taking Behaviors of First-Generation Sub-Saharan African-Born U.S. Resident Men
    • Highly Influenced